Registration is open for
ASIPP's 2025 Annual Meeting
We would love it if you would register and join us in Orlando!
| |
Attention Fellows and Residents! | |
|
ASIPP is pleased to announce a scholarship to help fellows and residents participate in the 2025 ASIPP Annual Meeting. Recipients of this scholarship will receive reimbursement for up to three nights stay at the host hotel at the official ASIPP single-occupancy room block rate. This includes room block room rate and tax.
The number of scholarship recipients will be limited so it is important to apply soon!
| |
Abstract submissions are open for
ASIPP's 2025 Annual Meeting!
The abstract submission deadline is March 10, 2025.
Don't miss this opportunity to share your insights
and help shape the future of pain management.
| |
Dr. Joel Smithers Illegally Prescribed Schedule II Narcotics
Joel Smithers, a Martinsville-based doctor, was found guilty of multiple drug charges at the conclusion of a three-week jury trial last week in U.S. District Court in Abingdon (Virginia), Acting United States Attorney Zachary T Lee announced.
The jury convicted Smithers, 42, after sixteen hours of deliberation, on one count of maintaining a place for the purpose of illegally distributing controlled substances and 466 counts of illegally prescribing Schedule II controlled substances.
“Patients trust doctors to make decisions based on their healthcare needs, not a perversion of their own greed,” Acting United States Attorney Zachary T. Lee said today. “For many years, this defendant betrayed the trust placed in him by his patients, his community, and the medical profession as a whole through his illegal distribution of thousands of medically unnecessary opioids. I am grateful to the entire prosecution team for bringing this case to justice.”
Read More
| |
Mark Your Calendar for These
Upcoming ASIPP Webinars!
Agendas coming soon
| |
Luigi Mangione’s alleged killing of UnitedHealthcare CEO Brian Thompson has sent waves through the medical community. This horrific act of violence, while tragic and inexcusable, forces us to confront an uncomfortable reality: frustration with the unchecked power of publicly traded insurance companies has reached a boiling point, for patients and doctors alike.
As a pain management physician, I deeply empathize with the anguish of denied care. While my patients desperately seek relief, insurance companies reject treatments that are evidence based, cataloging them as “unnecessary” or “experimental.” They use opaque and unreliable artificial intelligence algorithms to deny care and rely on the medical record notes to contextualize the humanity of my patients. The process of scheduling appeals with insurance representatives or “peer” reviewers is frequently a time-consuming exercise in futility. Decision-making “peers” can be individuals without expertise in the relevant medical field, incentivized to deny care. The appeals process can take months, leaving patients to suffer while the clock ticks on their quality of life.
The stakes are not just financial — they’re profoundly human. Insurance denials often force doctors to fall back on older, cheaper options that are less effective and carry higher risks. For pain patients, this can mean a return to opioids, which insurers readily cover. And while opioids are reasonable in certain circumstances, they also have well-documented side effects and an established role in America’s addiction crisis. When insurers lag behind medical evidence, they not only undermine patient care but perpetuate public health emergencies like the opioid crisis.
Read More
| |
The agency seeks to make its first HIPAA Security Rule update since 2013 to clarify what health plans, healthcare clearinghouses, providers and their business associates must do to protect the security of electronic protected health information.
The Department of Health and Human Services and the Office for Civil Rights have announced they will be soliciting comments on a proposal to modify the Security Standards for the Protection of Electronic Protected Health Information under the Health Insurance Portability and Accountability Act of 1996 and the Health Information Technology for Economic and Clinical Health Act of 2009.
To strengthen healthcare cybersecurity and address concerns over the alarming growth in the number of breaches reported to OCR, the proposed modifications – to be published in the Federal Register on January 6, 2025 – aim to address significant changes in technology, breach trends, enforcement, best practices and methodologies for protecting ePHI and take into account court decisions that affect Security Rule enforcement.
Why It Matters
With the White House review of the proposed modifications to the HIPAA Security Rule complete, HHS will issue a Notice of Proposed Rulemaking that includes several new proposals and clarifications, such as removing the distinction between "required" and "addressable" specifications and making all of them mandatory, with limited exceptions.
Read More
| |
Colorado is the second state to legalize psilocybin therapy
As Colorado becomes the second state to legalize psychedelic therapy this week, a clash is playing out in Colorado Springs, where conservative leaders are restricting the treatment over objections from some of the city's 90,000 veterans, who've become flagbearers for psychedelic therapy to treat post-traumatic stress disorder.
Colorado residents voted to legalize the therapeutic use of psilocybin, the chemical compound found in psychedelic mushrooms, in a 2022 ballot measure, launching 2 years of rulemaking before it could be used to treat conditions such as depression and post-traumatic stress disorder (PTSD).
This week, companies and people will be able to apply for licenses to administer the mind-altering drug, though treatment will likely not be available for some months as applications are processed.
Read More
| |
|
New 2025 Dates
Mark your calendars!
January 25, February 15,
March 1, and March 29
Four (4) hour virtual exam
- ABIPP Path – Combined CCPM/ CSM Exam
For those with subspecialty in Pain Medicine
Two (2) hour virtual exam
- ABIPP Competency Exam in IPM
For those without primary board certification
Two (2) hour virtual exam
- ABIPP Competency Exam in Regenerative Medicine
Two (2) hour virtual exam
- Controlled Substance Management Competency Exam
Two (2) hour virtual exam
- Documentation, Coding, Compliance, Practice Management Competency Exam
Two (2) hour virtual exam
| |
|
Discussions with young patients and their parents can make a big difference
The healthcare profession has done an admirable job controlling infectious epidemics and pandemics, such as AIDS and COVID-19 (special shout-out to Operation Warp Speed for the creation of COVID vaccines in record time). Now, we need to move on to social media epidemics.
I believe the epidemic of social media has the potential to be as dangerous as infectious epidemics. Mental health should be treated with the same urgency as physical health. The time has arrived for physicians to take an active role in recognizing the dangers of social media, especially for youth, and to have discussions with young patients and their parents about the impact of social media on the growth and development of children.
Over the last decade, growing evidence has identified the potential negative impacts of social media on adolescents. According to a study of American teenagers ages 12 to 15, those who used social media more than 3 hours per day faced double the risk of having adverse mental health outcomes, including depression and anxiety symptoms. While most social media platforms require users to be a minimum of 13 years old in order to sign up (per Congress' Children's Online Privacy Protection Act), users are often younger than this. Moreover, experts suggest even 13 is too young for kids to be on these platforms.
Read More
| |
|
Recent findings indicate that treating chronic back pain (CBP) with open-label placebo (OLP) significantly reduced pain scores four weeks after intervention in some patients. In addition, it was demonstrated that OLP likely delivers pain relief through similar neural pathways as blinded placebo treatment.
“Open-label placebos—placebos without deception—may be a valuable, ethical way to prescribe placebo. They have benefits on clinical outcomes and they engage pain-regulatory brain mechanisms,” said study author Yoni K. Ashar, PhD, an assistant professor at the University of Colorado Anschutz Medical Campus, in Aurora.
The randomized clinical trial enrolled 101 adults with moderate CBP (52 females; mean age, 40.4 years). Participants’ mean CBP before intervention was 4.10 on a 10-point scale (0=no pain; 10=the most intense pain) and experienced pain for a duration of 9.7 years (JAMA Netw Open 2024;7[9]:e2432427). Just over half of patients (n=51) received an OLP subcutaneous lumbar (saline) injection accompanied by information about the power of placebo to relieve pain, along with their usual care. The other 50 patients received no injection and continued usual care. Randomization between groups was balanced with regard to age, sex, baseline pain and opioid use.
Read More
| |
- ASIPP Members Only Site Information - | |
-
To log in for the first time you will need to click “forgot password” at the bottom of the login window.
- Check your email and then log in as directed.
-
If you have problems logging into your account, click here.
| |
|
Data from a study indicate that physician empathy is more strongly associated with the outcomes of patients with chronic low back pain (LBP) than nonpharmacologic treatments, opioid therapy or lumbar spine surgery (JAMA Netw Open 2024; 7[4]: e246026).
What’s more, study participants treated by very empathic physicians (VEPs) reported having significantly better outcomes pertaining to pain, function and health-related quality of life (HRQOL) compared with patients treated by only slightly empathic physicians (SEPs).
“Physician empathy is an important aspect of the patient-physician relationship among those with chronic pain. Greater efforts to cultivate and improve physician empathy appear warranted in this population,” the study authors concluded.
Read More
| | |
| |
REGISTRATION
COMING SOON!
| | |
|
In an increasingly competitive healthcare landscape, a strong digital presence and a superior care experience can be decisive factors in attracting and retaining patients, says one health IT consultant.
Hospitals and health systems have been discussing digital-first patient engagement for a while now, but fewer organizations than you might think have made huge strides forward on that front.
Likewise, data-driven decision-making is a phrase that's been tossed around quite a bit in healthcare, but in many cases it's a dream that's yet to become reality.
Meanwhile, as providers aim to make trust and transparency core to their day-to-day operations, they're often not as advanced in those efforts as they might hope.
Read More
| |
|
Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.
Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.
Interested in becoming a member of the PMCR Editorial Board?
Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.
For more information or to submit your articles, click here.
| |
|
Danielle Levin, MD, Jonathan Alabre, MD, and Ryan Gualtier, MD
Abstract
BACKGROUND: A hiccup is a common well-documented physiologic process that occurs due to a sudden involuntary contraction of the diaphragm and intercostal muscles, with subsequent rapid closure of the glottis. While acute hiccups, lasting < 48 hours, are experienced by almost all individuals at some point in their life, prolonged hiccups lasting > 48 hours, or intractable hiccups lasting > 1 month, are quite rare and may significantly impact a person’s quality of life. We would like to share a report of a stellate ganglion (SG) block relieving the discomfort of a patient suffering from idiopathic intractable hiccups.
CASE REPORT: A 73-year-old man suffered from > 3 years of idiopathic intractable hiccups that were resistant to oral medications and phrenic nerve blocks. An ultrasound-guided SG block with a combination of ropivacaine and lidocaine was administered to the patient. After this block, for the first time in over 3 years, the patient was 100% hiccup-free for one week.
CONCLUSIONS: This case report demonstrates that the ultrasound-guided SG block could be a temporary treatment option for those affected by idiopathic intractable hiccups.
KEY WORDS: Stellate ganglion block, ultrasound, intractable hiccups, local anesthetic
Read More
| |
|
Laxmaiah Manchikanti, MD, Emilija Knezevic, ., Nebojsa Nick Knezevic, MD, PhD, Alan D. Kaye, MD, PhD, Sairam Atluri, MD, Mahendra R. Sanapati, MD, Vidyasagar Pampati, MSc, and Joshua A. Hirsch, MD
Abstract
BACKGROUND: Recent research underscores the potential of intradiscal biologics, such as mesenchymal stem cells (MSCs), platelet-rich plasma (PRP), and alpha-2-macroglobulin, in promoting chondrogenesis within lumbar intervertebral discs as a treatment for discogenic low back pain. Studies indicate significant improvements in pain relief, physical function, and overall quality of life following these interventions.
OBJECTIVE: This study aims to evaluate the effectiveness of intradiscal injections of MSCs and PRP in managing low back and lower extremity pain. A systematic review and meta-analysis were conducted to assess the outcomes of these treatments.
STUDY DESIGN: A systematic review and meta-analysis evaluating the efficacy of PRP and MSC injections for discogenic low back and lower extremity pain.
DATA SOURCES: The review included literature from PubMed, Cochrane Library, the U.S. National Guideline Clearinghouse (NGC), prior systematic reviews, and reference lists, covering studies from 1966 to September 2024.
STUDY SELECTION: Randomized controlled trials (RCTs), observational studies, and case reports focusing on biologic injections into the disc were included.
DATA EXTRACTION AND SYNTHESIS: Data were extracted and assessed for methodological quality. Evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria and summarized based on best evidence synthesis principles on a 1-to-5 scale.
RESULTS: The analysis included 8 RCTs (4 evaluating PRP, 5 evaluating MSCs) and 8 observational studies (4 assessing PRP, 4 assessing MSCs) for managing chronic low back pain. Evidence quality was deemed fair (Level III) with limited certainty and moderate recommendation strength based on qualitative and quantitative analyses.
LIMITATIONS: Paucity of high-quality studies.
CONCLUSION: This systematic review and single-arm meta-analysis suggest that intradiscal injections of MSCs and PRP may be effective in managing discogenic low back pain, supported by Level III evidence.
KEY WORDS: Chronic low back pain, discogenic pain, regenerative therapy, mesenchymal stem cells, platelet-rich plasma, intradiscal injection
Read More
| |
|
Michael Silveira Santiago, MD, Fernanda Valeriano Zamora, MD, Elcio Machinski, Andre Richard da Silva Oliveira Filho, Mariana Taina Oliveira de Freitas, Deivyd Vieira Silva Cavalcante, BPH, Felipe da Fonseca Delmondes, MD, and Rosana Cipolotti, MD, PhD
Abstract
BACKGROUND: Hip osteoarthritis is a joint disease that causes worsening pain and inhibits activities of daily living. Due to poor pain control and the function of usual clinical treatment, joint infiltration with orthobiologics is a therapeutic alternative. Among these, bone marrow aspirate (BMA) represents a cellular therapy with promising clinical results.
OBJECTIVE: Our study aimed to assess the clinical response of joint infiltration with BMA for hip osteoarthritis.
STUDY DESIGN: We conducted a systematic review and meta-analysis of the main outcomes in hip osteoarthritis after infiltration with BMA and bone marrow concentrate (BMC).
METHODS: We systematically searched PubMed, Embase, Cochrane, and Science Direct for studies evaluating patients with hip osteoarthritis who received joint infiltration with BMA or BMC. In the absence of studies with a control group, we performed a pairwise meta-analysis comparing results of a single group at follow-up vs baseline.
RESULTS: We included 4 studies with improvement in Numeric Rating Scale pain scores associated with BMA or BMC therapy at 3 months (mean difference [MD], -3.48 points; 95% CI, -5.81 to -1.15), 6 months (MD, -3.25 points; 95% CI, -4.07 to -2.42), and 12 months (MD, -2.79 points; 95% CI, -3.83 to -1.74). There was also a significant improvement in measurable quality of life through validated questionnaires at 3 months (standardized mean difference [SMD], -0.91; 95%, CI -1.59 to -0.23), 6 months (SMD, -1.38; 95% CI, -1.79 to -0.98), and 12 months (SMD, -1.30; 95% CI, -2.44 to -0.16).
LIMITATIONS: Among our study’s limitations is the lack of a randomized controlled trial in the meta-analysis. Also, since there was no comparator, we could not conduct a pairwise meta-analysis. Finally, the small sample size limits the generalization of the findings.
CONCLUSION: In this meta-analysis, joint infiltration with BMA or BMC was associated with an improvement in pain and quality of life in patients with hip osteoarthritis. Further randomized studies are needed to improve the quality of evidence.
KEY WORDS: Hip osteoarthritis, bone marrow aspirate, bone marrow concentrate
Read More
| |
|
ASIPP is now in collaboration with Curi Medical Liability Program
Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices.
Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.
| | |
|
Group Purchasing Organization Offer Better Pricing and Creates Added Value
ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.
Learn More
| | |
|
ASIPP, Fedora Healthcare Solutions Partnership
ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.
We have received a tremendous amount of interest in the ASIPP billing and coding program.
Click here to learn more about the negotiated rate for practices and more!
| |
|
Like and follow ASIPP® on Facebook, X, and LinkedIn for the most
up-to-date news related to you, your practice, and your patients!
| | | | |